Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments

Eli Lilly and Company (NYSE: LLY) has announced a definitive agreement to acquire DICE Therapeutics, Inc. (NASDAQ: DICE), a biopharmaceutical company known for its DELSCAPE technology platform and oral therapeutic candidates. This strategic acquisition aims to expedite the development of novel treatments for chronic autoimmune diseases.

Eli Lilly and DICE Therapeutics: A Perfect Synergy

Patrik Jonsson, an executive at Eli Lilly, lauded the innovation, talent, and drug discovery expertise of DICE Therapeutics. DICE’s specialization in oral IL-17 inhibitors could prove instrumental in addressing significant unmet medical needs.

DICE’s Novel Approach to Drug Discovery

Kevin Judice, CEO of DICE Therapeutics, expressed optimism for the future, specifically regarding their pipeline of IL-17 inhibitors DC-806 and DC-853. DICE’s unique approach to discovering and advancing oral, small molecules for protein-protein interaction targets will now benefit from Lilly’s industry-leading clinical development capabilities.

Acquisition Details

Lilly will initiate a tender offer to acquire all outstanding shares of DICE at $48 per share in cash, totaling approximately $2.4 billion. This represents a premium of about 40% to the 30-day volume-weighted average trading price of DICE’s common stock as of June 16, 2023.

The transaction is expected to close in the third quarter of 2023, pending standard closing conditions. Once the tender offer concludes, any remaining shares of DICE will be purchased through a second-step merger at the same price.

About DICE Therapeutics

DICE Therapeutics is a biopharmaceutical company renowned for its innovative DELSCAPE technology platform. It focuses on developing oral therapeutics for chronic immunological and other diseases. Their lead therapeutic candidates target IL-17, a pro-inflammatory signaling molecule implicated in numerous immunology indications. They’re also working on oral therapeutic candidates targeting integrin α4ß7 for treating inflammatory bowel disease.

Incorporating this transaction into Eli Lilly’s financial guidance and results will happen according to Generally Accepted Accounting Principles (GAAP). Eli Lilly will determine whether to treat this transaction as a business combination or an asset acquisition, including any associated in-process research and development charges, upon closing. Legal counsel for this transaction includes Kirkland & Ellis LLP for Lilly and Centerview Partners LLC and Fenwick & West LLP for DICE.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.